SECTOR:
Oncology
FUND/VEHICLE:
Pivotal US; NFLS Direct Investment
INVESTMENT DATE:
2018
GEOGRAPHY:
North America
STATUS CURRENT/FORMER INVESTMENT:
Existing
WEBSITE:
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman’s Lab at Stanford University, which demonstrated complete cures in numerous cancer models. The company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.